Saturday, June 25, 2022

Aurinia Pharmaceuticals Inc. [AUPH] Director makes an insider purchase of 5,000 shares worth 54985.0.

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Aurinia Pharmaceuticals Inc. shares valued at $54,985 were purchased by MacKay-Dunn R. Hector on Mar 09. At $11.00 per share, MacKay-Dunn R. Hector acquired 5,000 shares. The insider’s holdings grew to 11,000 shares worth approximately $0.12 million following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, MILNE GEORGE M JR purchased 5,000 shares, netting a total of over 54,100 in proceeds. Following the buying of shares at $10.82 each, the insider now holds 50,000 shares.

Before that, Donley Matthew Maxwell had sold 3,052 shares from its account. In a trade valued at $36,655, the Ex VP, Intern’l Operations traded Aurinia Pharmaceuticals Inc. shares for $12.01 each. Upon closing the transaction, the insider’s holdings decreased to 3,052 shares, worth approximately $0.18 million.

As published in a research note from Argus on May 18, 2022, Flex Ltd. [FLEX] has been rated up from a Hold to a Buy and the price target has been revised to $22. This represents a 33.73% premium over Wednesday’s closing price. Analysts at Cross Research upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in early May. As of February 26, 2021, JP Morgan has increased its “Neutral” rating to a “an Overweight” for FLEX. Earlier on December 18, 2020, JP Morgan downgraded its rating. Their new recommendation was “a Neutral” for FLEX stock which previously was a “an Overweight”. This represents a 55.4% premium over Wednesday’s closing price. Analysts at Oppenheimer upgraded the stock from ‘”a Perform”‘ to ‘”an Outperform”‘ outlook in a report released in early December. As of October 28, 2021, Oppenheimer has decreased its “an Outperform” rating to a “Perform” for AUPH. Earlier on January 25, 2021, H.C. Wainwright resumed its rating. Their recommendation was “a Buy” for AUPH stock.

Analyzing AUPH’s Price Performance

On Wednesday, Aurinia Pharmaceuticals Inc. [NASDAQ: AUPH] rose 3.34% to $11.15. The stock’s lowest price that day was $10.58, but it reached a high of $11.54 in the same session. During the last five days, there has been a surge of approximately 17.99%. Over the course of the year, Aurinia Pharmaceuticals Inc. shares have dropped approximately -51.25%. Shares of the company reached a 52-week high of $23.42 on 01/03/22 and a 52-week low of $8.86 on 05/09/22. A 50-day SMA is recorded $11.11, while a 200-day SMA reached $17.44. Nevertheless, trading volume fell to 2.18 million shares from 2.48 million shares the previous day.

Support And Resistance Levels for Aurinia Pharmaceuticals Inc. (AUPH)

According to the 24-hour chart, there is a support level at 10.64, which, if violated, would cause prices to drop to 10.13. In the upper region, resistance lies at 11.60. The next price resistance is at 12.05. RSI (Relative Strength Index) is 50.67 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.24, which suggests the price will decrease in the coming days. Percent R is at 53.48%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Which companies own the most shares of Aurinia Pharmaceuticals Inc. (AUPH)?

According to Fidelity Management & Research Co filings, the company currently owns 5,291,226 shares, which is about 3.73% of the total AUPH shares outstanding. The investor’s shares have appreciated by 667,799 from its previous 13-F filing of 4623427.0 shares. With the completion of the sale, Morgan Stanley & Co. LLC’s stake is now worth $29,938,586. Bellevue Asset Management AG interest valued at $27.14 million while Susquehanna Financial Group LLLP sold a -1,433,214 stake. A total of 1,227,129 shares of Aurinia Pharmaceuticals Inc. were sold by Renaissance Technologies LLC during the quarter, and 682,793 were bought by Stifel Nicolaus & Co., Inc. In its current portfolio, FIAM LLC holds 1,162,528 shares valued at $13.11 million.

In terms of Aurinia Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $23.81 in the next 12 months, up nearly 117.79% from the previous closing price of $10.79. Analysts anticipate Aurinia Pharmaceuticals Inc. stock to reach $30.00 by 2022, with the lowest price target being $15.00. In spite of this, 8 analysts ranked Aurinia Pharmaceuticals Inc. stock as a Buy at the end of 2022. On November 03, 2020, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $28.

Latest news

Related news

LEAVE A REPLY

Please enter your comment!
Please enter your name here

2618

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam